arXiv · 2208.05726
Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
Abstract
In parametric Bayesian designs of early phase cancer clinical trials with drug combinations exploring a discrete set of partially ordered doses, several authors claimed that there is no added value in including an interaction term to model synergism between the two drugs. In this paper, we investigate these claims in the setting of continuous dose levels of the two agents. Parametric models will be used to describe the relationship between the doses of the two agents and the probability of dose limiting toxicity and efficacy. Trial design proceeds by treating cohorts of two patients simultaneously receiving different dose combinations and response adaptive randomization. We compare trial safety and efficiency of the estimated maximum tolerated dose (MTD) curve between models that include an interaction term with models without the synergism parameter with extensive simulations. Under a selected class of dose-toxicity models and dose escalation algorithm, we found that not including an interaction term in the model can compromise the safety of the trial and reduce the pointwise reliability of the estimated MTD curve.
Explore related subjects
Keep this discovery
Mourad Tighiouart, José L. Jiménez, Marcio A. Diniz, André Rogatko. 2022-08-11. Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?. https://arxiv.org/abs/2208.05726
Cite the original work for its findings. Save a collection to share your selection of sources.